EA201391584A1 - Новое соединение, предназначенное для лечения дегенеративных и воспалительных заболеваний - Google Patents

Новое соединение, предназначенное для лечения дегенеративных и воспалительных заболеваний

Info

Publication number
EA201391584A1
EA201391584A1 EA201391584A EA201391584A EA201391584A1 EA 201391584 A1 EA201391584 A1 EA 201391584A1 EA 201391584 A EA201391584 A EA 201391584A EA 201391584 A EA201391584 A EA 201391584A EA 201391584 A1 EA201391584 A1 EA 201391584A1
Authority
EA
Eurasian Patent Office
Prior art keywords
degenerative
treatment
conditions
inflammatory diseases
diseases
Prior art date
Application number
EA201391584A
Other languages
English (en)
Other versions
EA024743B1 (ru
Inventor
Кристель Жанн Мари Мене
Аластэр Джеймс Ходжес
Хью Дэвид Вайтер
Original Assignee
Галапагос Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галапагос Нв filed Critical Галапагос Нв
Publication of EA201391584A1 publication Critical patent/EA201391584A1/ru
Publication of EA024743B1 publication Critical patent/EA024743B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Раскрыто соединение пиразолопиридина в соответствии с формулой I, способное ингибировать JAK, а также его фармацевтически приемлемые соли, сольват, сольваты фармацевтически приемлемых солей и его биологически активный метаболит. Соединение может быть получено в виде фармацевтической композиции и может применяться для лечения или профилактики разнообразных состояний у млекопитающих, включающих людей, и, конкретно, таких состояний, которые могут быть ассоциированы с аберрантной активностью JAK, включающих посредством приведения неограничивающего примера аллергию, воспалительные состояния, аутоиммунные заболевания, пролиферативные заболевания, отторжение трансплантата, заболевания, включающие нарушения обновления хряща, врожденные дефекты хряща и/или заболевания, ассоциированные с гиперсекрецией IL6.
EA201391584A 2011-04-28 2012-04-26 Соединение, предназначенное для лечения дегенеративных и воспалительных состояний EA024743B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161479956P 2011-04-28 2011-04-28
PCT/EP2012/057652 WO2012146657A1 (en) 2011-04-28 2012-04-26 Novel compound useful for the treatment of degenerative and inflammatory diseases

Publications (2)

Publication Number Publication Date
EA201391584A1 true EA201391584A1 (ru) 2014-04-30
EA024743B1 EA024743B1 (ru) 2016-10-31

Family

ID=46017860

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391584A EA024743B1 (ru) 2011-04-28 2012-04-26 Соединение, предназначенное для лечения дегенеративных и воспалительных состояний

Country Status (18)

Country Link
US (5) US8975406B2 (ru)
EP (2) EP2702059B1 (ru)
JP (2) JP5947372B2 (ru)
KR (1) KR101934707B1 (ru)
CN (2) CN103492385B (ru)
AR (1) AR086042A1 (ru)
AU (2) AU2012247484B2 (ru)
BR (1) BR112013027338A2 (ru)
CA (2) CA2833942A1 (ru)
EA (1) EA024743B1 (ru)
HK (2) HK1195312A1 (ru)
IL (1) IL228786A (ru)
MX (2) MX360697B (ru)
SG (1) SG194508A1 (ru)
TW (1) TWI536990B (ru)
UY (1) UY34037A (ru)
WO (2) WO2012146659A1 (ru)
ZA (1) ZA201307793B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CN105338965A (zh) * 2013-04-29 2016-02-17 赛诺菲股份有限公司 可吸入药用组合物和含有该药用组合物的吸入器装置
GB201321733D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR101690760B1 (ko) * 2014-11-05 2016-12-30 조길래 피부자극완화, 탈모방지 및 발모촉진 효과를 나타내는 카페오일펜타펩타이드 및 이를 함유하는 탈모방지 및 발모촉진용 화장료 조성물
TW201705961A (zh) * 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
WO2016205590A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
JP6999424B2 (ja) 2015-06-18 2022-01-18 エイティナイン バイオ リミテッド １，４－置換ピペリジン誘導体
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
DE102015215820A1 (de) * 2015-08-19 2017-02-23 Siemens Healthcare Gmbh Steuern eines medizintechnischen Geräts
JP6978098B2 (ja) * 2016-07-26 2021-12-08 スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. 選択的ｊａｋ阻害剤としての化合物、該化合物の塩類および治療への使用
JOP20190077A1 (ar) * 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018163971A1 (ja) * 2017-03-09 2018-09-13 富士フイルム株式会社 音響レンズ用樹脂材料、音響レンズ、音響波プローブ、音響波測定装置、超音波診断装置、光音響波測定装置および超音波内視鏡
EA037208B1 (ru) * 2017-09-29 2021-02-19 Эррей Биофарма Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA035568B1 (ru) * 2017-09-29 2020-07-08 Эррей Биофарма Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN112771043B (zh) * 2018-09-30 2023-04-28 北京志健金瑞生物医药科技有限公司 取代吡唑稠环类衍生物及其制备方法和应用
SG11202104687SA (en) * 2018-12-07 2021-06-29 Sunshine Lake Pharma Co Ltd Ret inhibitors, pharmaceutical compositions and uses thereof
CN111285874A (zh) * 2018-12-07 2020-06-16 广东东阳光药业有限公司 Ret抑制剂、其药物组合物及其用途
EP4141003A4 (en) * 2020-04-22 2024-05-15 Shenzhen Zhongge Biological Tech Co Ltd PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND ASSOCIATED COMPOSITION AND USE
CN113713083A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗脱发的药物组合
BR112023003835A2 (pt) 2020-09-01 2023-04-04 Syngenta Crop Protection Ag Derivados heterocíclicos com substituintes contendo enxofre ativos em termos pesticidas
AU2021347913A1 (en) 2020-09-28 2023-05-18 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
EP4284802A1 (en) * 2021-02-01 2023-12-06 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
EP4284801A1 (en) * 2021-02-01 2023-12-06 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
EP4384523A1 (en) 2021-08-10 2024-06-19 Syngenta Crop Protection AG 2,2-difluoro-5h-[1,3]dioxolo[4,5-f]isoindol-7-one derivatives as pesticides
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
WO2023187191A1 (en) 2022-04-01 2023-10-05 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2427046T3 (es) 2004-06-21 2013-10-28 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
EP2057158B8 (en) * 2006-08-30 2015-09-30 Cellzome Limited Triazole derivatives as kinase inhibitors
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
SG178812A1 (en) 2008-06-20 2012-03-29 Genentech Inc Triazolopyridine jak inhibitor compounds and methods
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica

Also Published As

Publication number Publication date
KR101934707B1 (ko) 2019-01-03
JP5947372B2 (ja) 2016-07-06
US8975406B2 (en) 2015-03-10
CA2833942A1 (en) 2012-11-01
US20180078547A1 (en) 2018-03-22
US20140051677A1 (en) 2014-02-20
EP2702058B1 (en) 2015-08-19
IL228786A0 (en) 2013-12-31
CN103492386A (zh) 2014-01-01
MX2013012281A (es) 2013-11-21
TW201247202A (en) 2012-12-01
WO2012146659A1 (en) 2012-11-01
MX2013012282A (es) 2013-11-21
KR20140025430A (ko) 2014-03-04
US8802682B2 (en) 2014-08-12
UY34037A (es) 2012-11-30
TWI536990B (zh) 2016-06-11
HK1195311A1 (zh) 2014-11-07
CN103492386B (zh) 2016-03-09
AU2012247482A1 (en) 2013-03-28
ZA201307793B (en) 2015-04-29
AR086042A1 (es) 2013-11-13
US20160213666A1 (en) 2016-07-28
JP2014512404A (ja) 2014-05-22
EP2702059A1 (en) 2014-03-05
IL228786A (en) 2017-04-30
US20150031706A1 (en) 2015-01-29
AU2012247484A1 (en) 2013-03-28
MX360697B (es) 2018-11-14
CA2833963C (en) 2019-09-17
CN103492385A (zh) 2014-01-01
EP2702059B1 (en) 2015-08-19
WO2012146657A1 (en) 2012-11-01
EA024743B1 (ru) 2016-10-31
CN103492385B (zh) 2016-05-11
US20120277247A1 (en) 2012-11-01
US9987272B2 (en) 2018-06-05
NZ617528A (en) 2015-09-25
BR112013027338A2 (pt) 2017-08-08
HK1195312A1 (zh) 2014-11-07
MX355653B (es) 2018-04-26
AU2012247484B2 (en) 2015-02-19
JP5947371B2 (ja) 2016-07-06
AU2012247482B2 (en) 2015-03-05
CA2833963A1 (en) 2012-11-01
EP2702058A1 (en) 2014-03-05
JP2014512405A (ja) 2014-05-22
SG194508A1 (en) 2013-12-30
US9241931B2 (en) 2016-01-26

Similar Documents

Publication Publication Date Title
EA201391584A1 (ru) Новое соединение, предназначенное для лечения дегенеративных и воспалительных заболеваний
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
UA107935C2 (en) 5-phenyl [1,2,4] triazolo [1,5-a] pyridin-2-yl-as jak inhibitors
EA201590071A1 (ru) Аминотриазолопиридин для применения в лечении воспаления и его фармацевтические композиции
EA201491247A1 (ru) Производные дигидробензооксазина и дигидропиридооксазина
CU20130126A7 (es) Inhibidores sustituidos de acetil-coa carboxilasa
EA201892339A2 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA201690094A1 (ru) Ингибиторы syk
EA201270076A1 (ru) Новое соединение, применимое для лечения дегенеративных и воспалительных заболеваний
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201391072A1 (ru) Производные фтор-пиридинона, полезные в качестве антибактериальных агентов
EA201390198A1 (ru) Гетероциклическое соединение
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201300863A1 (ru) Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
EA201300862A1 (ru) Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201491013A1 (ru) Пиразиновые ингибиторы киназы
EA201490152A1 (ru) Антагонисты trpm8 и их применение при лечении
EA201590562A1 (ru) Бензамиды
EA201390755A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU